Wire · opportunities
U.S. Registry Data Confirm Liver Risk With Controversial Vasculitis Drug
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 24 August 2026 · Fusion42 review
New U.S. registry data confirm liver injury risks related to Amgen's vasculitis drug avacopan, reinforcing FDA concerns and pressures for withdrawal after reports of severe liver damage and fatalities.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a sharp regulatory risk if your drug overlaps with avacopan's market; the FDA's unresolved liver safety signals could open a door for safer competitors or force market exits.
◆ Coverage
1 source · 24 Aug 2026
◆ Related on Wire
◆ Topics
Biotechdrug-safetyFDAliver-riskvasculitisAmgen